A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152)
and to establish the MTD at each of the different dosing schedules.